Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (Q24200385)

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

EULAR evidence-based recommendations for the management of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Serotonergic agents in the treatment of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Anti-depressants and centrally active agents for fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Treatment of fibromyalgia with antidepressants: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

A meta-analysis of fibromyalgia treatment interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Comment on the 1990 American College of rheumatology criteria for fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Histological abnormalities in muscle from patients with certain types of fibrositis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder. A double-blind multicenter study with parallel groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021

Muscle tissue oxygen pressure in primary fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009807

7 January 2021